EBITDA rose 18.8% YoY to ₹118.3 crore, up from ₹99.6 crore. Operating margins also improved to 23%, compared to 21.2% in Q4 2023.
However, the company’s net profit declined by 33.7% to ₹91.3 crore, down from ₹137.7 crore a year ago.
On the brighter side, the board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder approval at the upcoming Annual General Meeting.
Sanofi India’s recent partnerships in cardiovascular (CV) and central nervous system (CNS) segments have set the stage for expansion, with the company stating that their execution has met expectations.
Also read: Schaeffler India posts double-digit Q4 growth; recommends ₹28 final dividend
The company also continues to advance its ‘India for India’ strategy, focusing on go-to-market initiatives, operational efficiency, and innovation.
“In a year of significant transformation, we successfully launched Soliqua®—our best-in-class diabetes drug for the premix segment, which has seen encouraging acceptance,” said Rodolfo Hrosz, Managing Director, Sanofi India. He added that partnerships in CNS and CV segments are progressing well, with initial promising results.
Sanofi, which has been present in India for nearly seven decades, remains focused on expanding its product availability while driving efficiency improvements across its operations.
